Pisa

• Palbociclib plus fulvestrant in women with hormone receptor positive and human epidermal growth factor receptor type 2 negative locally adva … Recruiting
  2024-513372-18-00 4 2019-10-18 Pre- and post-menopausal women with HR+/HER2- LABC or MBC whose diseas
• LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma Recruiting
  2023-508101-24-00 5 2019-08-01 Lymphoblastic lymphoma
• A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer Recruiting
  2023-508302-24-00 4 2019-05-07 Locally Advanced/Metastatic Urothelial Cancer
• A study to evaluate Samyr effectiveness and safety profile. The study is done by comparing that Samyr injection is better than placebo injec … Recruiting
  2024-513022-29-00 5 2019-01-09 Major Depression Disorders
• rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma Recruiting
  2024-516078-31-00 10 2015-05-05 Recurrent and Primary Refractory Ewing Sarcoma
• Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended recruitment
  2025-521067-13-00 5 2026-04-24 Atherosclerotic Cardiovascular Disease (ASCVD)
• A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons with HIV-1 (INNOVATE Study) Ended recruitment
  2025-521918-26-00 4 2026-02-11 HIV Infections
• A study of BMS-986504 in combination with Nab-p/Gem versus placebo in combination with Nab-p/Gem in untreated metastatic PDAC with homozygou … Ended recruitment
  2025-522598-12-00 10 2025-12-17 Untreated Metastatic Pancreatic Ductal Adenocarcinoma
• Comparison of continuing intravenous antibiotic therapy with switching to oral antibiotics in clinically stable patients with blood infectio … Ended recruitment
  2024-517308-13-00 6 2025-12-10 Gram-negative bacteraemia
• Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Part … Ended recruitment
  2023-506146-23-00 4 2025-11-17 Non-Muscle-Invasive Urothelial Carcinoma (NMIBC) of the Bladder
• Master protocol of novel agents or combinations as perioperative treatment in participants with locally advanced resectable gastroesophagea … Ended recruitment
  2024-516909-23-00 4 2025-10-28 Locally Advanced Resectable Gastroesophageal Adenocarcinoma
• A Study of Zolbetuximab Together with Pembrolizumab and Chemotherapy in Adults with Gastric Cancer Ended recruitment
  2024-519773-19-00 5 2025-07-31 Gastroesophageal Junction Adenocarcinoma
• Rezafungin for treatment of chronic pulmonary aspergillosis (CPA) in adults with limited treatment options Ended recruitment
  2024-519575-26-00 4 2025-07-25 Chronic pulmonary aspergillosis (CPA)
• A Study to Compare Risankizumab to Vedolizumab in Adult Subjects With Moderate to Severe Ulcerative Colitis Ended recruitment
  2024-518998-33-00 5 2025-07-23 Ulcerative Colitis
• A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection Ended recruitment
  2024-520062-54-00 4 2025-07-23 Chronic Hepatitis D Virus (HDV) Infection
• A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants with PMM2-CDG Ended recruitment
  2024-520109-37-00 4 2025-07-09 PMM2-CDG
• Phase 1b/2 Study of Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Participants With Advanced Gastric Cancer (Substudy GC) Ended recruitment
  2024-517817-34-00 9 2025-06-18 Gastric Cancer
• Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced NSCLC (Substudy NSCLC) Ended recruitment
  2024-517818-15-00 9 2025-06-06 Non-Small Cell Lung Cancer
• Efficacy and Safety of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MA … Ended recruitment
  2024-515524-36-00 5 2025-05-30 Chronic Weight Management
• A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade … Ended recruitment
  2024-513282-39-00 5 2025-05-28 Hidradenitis Suppurativa (HS)
• Phase 2 Pan-Tumor Trial of R-DXd for Advanced/Metastatic Solid Tumors Ended recruitment
  2024-513307-13-00 4 2025-05-26 Advanced/metastatic solid tumors including gynecological cancers (endo
• A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY) Ended recruitment
  2024-516609-22-00 5 2025-04-15 Primary Sjögren’s Disease
• A research study comparing how well different doses of the medicine NNC0519-0130 can reduce kidney damage in people living with chronic kidn … Ended recruitment
  2024-510846-15-00 4 2025-04-14 Chronic Kidney Disease, with or without Type 2 diabetes, Obesity
• Phase 3 study of RMC-6236 in patients with previously treated metastatic PDAC Ended recruitment
  2024-516063-89-00 5 2025-04-10 Metastatic Pancreatic Ductal Adenocarcinoma

Showing 289–312 of 550 trials